撪梕 嬈愌 妛埵 丂

崙撪妛夛亂堦斒敪昞亃

戞69夞擔杮堛恀嬠妛夛憤夛丒妛弍廤夛 (2025.10.3-10.4) 崅抦
敧栘 桽彆, 忢晽 嫽暯, 峳愳 桰, 嶳娸 桼壚, 昹揷 岾岹
崅懍塼懱僋儘儅僩僌儔僼傿乕丒巼奜慄専弌朄傪梡偄偨奜棃儃儕僐僫僝乕儖帯椕栻暔儌僯僞儕儞僌偺専摙

昹揷 岾岹, 壴堜 梇婱, 敧栘 桽彆
奜棃儃儕僐僫僝乕儖TDM偱庣傞帯椕偺幙岦忋?摿掕栻嵻娗棟椏1偺嶼掕奼戝偺愴棯

彫扟 柧, 敧栘 桽彆, 忢晽 嫽暯, 昹揷 岾岹, 屟揷 廏庽
寣拞億僒僐僫僝乕儖偺揹婥壔妛専弌HPLC偺奐敪

嵅愳 嫪栫, 壛摗 棽姲, 忢晽 嫽暯, 敧栘 桽彆, 昹揷 岾岹
JADER傪梡偄偨ST崌嵻娭楢桳奞帠徾偺敪尰偲椵愊搳梌検偲偺娭楢偺専摙

戞42夞榓娍堛栻妛夛妛弍戝夛乮2025.8.26-8.27乯峀搰
愒奯 宐懢, 愇揷 抭熶, 怷戲 撜暯, 娵嶳戱幚, 愇郪 瀤, 悈尨 峃惏, 悰栰 恗旤, 惣嶳 岝宐, 忢晽 嫽暯, 昹揷 岾岹
挵撪嵶嬠憄偺曄壔偵傛傞娒憪娷桳惉暘偺媧廂傊偺塭嬁

戞40夞擔杮娐嫬姶愼妛夛憤夛丒妛弍廤夛 (2025.7.10-7.12) 墶昹
廐嶳 桽嵠, 旜 愮朏, 扟撪 嵤擳, 嶰岲幯栴崄, 峳愳 桰, 敧栘 桽彆, 嶳娸 桼壚
ICU 偵偍偗傞恖岺屇媧婍娭楢攛墛乮VAP乯梊杊僶儞僪儖偺弲庣棪偐傜傒偊偰偒偨 VAP 敪惗梫場偲梊杊嶔偺専摙

戞8夞僼儗僢僔儍乕僘丒僇儞僼傽儔儞僗堦斒幮抍朄恖擔杮堛椕栻妛夛 (2025.6.21-6.22) 嫗搒
嵅愳 嫪栫, 愇揷 抭熶, 忢晽 嫽暯, 怷戲 撜暯, 暉揷 恗, 怴栰 寬, 愳懞 婱巕, 愳揷 宧, 忋塇 揘栫, 昹揷 岾岹
擼弌寣媫惈婜偺寣埑娗棟偵偍偗傞栻嵻巘偲堛巘偺嫤摥僾儘僩僐乕儖偺桳梡惈

愒奯 宐懢, 愇揷 抭熶, 嵅愳 嫪栫, 怷戲 撜暯, 娵嶳 戱幚, 忢晽 嫽暯, 昹揷 岾岹
娒憪娷桳娍曽暈梡姵幰偵偍偗傞掅K寣徢敪徢偵娭偡傞屻曽帇揑挷嵏尋媶

戞99夞擔杮姶愼徢妛夛憤夛丒妛弍島墘夛, 戞73夞擔杮壔妛椕朄妛夛憤夛 崌摨妛夛 (2025.5.8-5.10) 墶昹
敧栘桽彆
MRSA 挵墛敪徢梊應僗僐傾嶌惉偺帋傒

壛摗 棽姲, 嵅愳 嫪栫, 愇揷 抭熶, 忢晽 嫽暯, 怷戲 撜暯, 愒奯 宐懢, 桍郪 惉壚, 壀 朑悈, 敧栘 桽彆, 昹揷 岾岹
堛栻昳暃嶌梡僨乕僞儀乕僗乮JADER乯傪梡偄偨Sulfamethoxazole and Trimethoprim偺埨慡惈偵娭偡傞夝愅

崙撪妛夛亂僔儞億僕僂儉亃

戞41夞擔杮TDM妛夛丒妛弍戝夛乮2025.7.26-7.27乯戝嶃
巹偵傕偱偒傞TDM偵娭楢偡傞堛椕忣曬傪妶梡偟偨尋媶
乽暥專僨乕僞偲儌僨儕儞僌丒僔儈儏儗乕僔儑儞乮M&S乯傪妶梡偟偨僼傽乕儅僐儊僩儕僋僗尋媶偺揥奐乿娵嶳戱幚

戞40夞擔杮娐嫬姶愼妛夛憤夛丒妛弍廤夛 (2025.7.10-7.12) 墶昹
姶愼懳嶔偵媮傔傜傟傞旝惗暔専嵏幒偲偺僐儈儏僯働乕僔儑儞丂
乽姶愼懳嶔偵偍偗傞栻嵻晹偲椪彴専嵏晹偲偺僐儈儏僯働乕僔儑儞帠椺偺徯夘乿昹揷 岾岹

栻嵻懴惈嬠偺姶愼惂屼偵偍偗傞僒僀僄儞僗偲暥壔
乽峈嬠栻揔惓巊梡偺僒僀僄儞僗偲暥壔乿昹揷 岾岹

栻嵻巘偑娭傢傞師悽戙偺姶愼惂屼丗媮傔傜傟傞妶摦偲僄價僨儞僗
乽枹棃偵岦偗偨 ICT丒AST 偺栻嵻巘偺怴偟偄帋傒傪峫偊傞乿昹揷 岾岹

崙撪妛夛亂儚乕僋僔儑僢僾亃

島墘

戞40夞擔杮娐嫬姶愼妛夛憤夛丒妛弍廤夛 (2025.7.10-7.12) 墶昹
乽掅巋寖惈庤巜徚撆嵻偺慖掕偺棷堄揰乿昹揷 岾岹

2025擭搙巐崙栻暔椕朄尋媶夛 (2025.5.31) 徏嶳
乽婡擻昡壙昦堾婡擻昡壙 ver.3 庴怰偵岦偗偨栻嵻嬈柋尒捈偟乿昹揷 岾岹

榑暥丒挊彂摍

Takada K, Samura M, Igarashi Y, Suzuki A, Ishigo T, Fujii S, Ibe Y, Yoshida H, Tanaka H, Ebihara F, Maruyama T, Hamada Y, Komatsu T, Tomizawa A, Takuma A, Chiba H, Yagi Y, Nishi Y, Enoki Y, Taguchi K, Tanikawa K, Kunishima H, Matsumoto K, Development and validation of a population pharmacokinetic model of vancomycin for patients of advanced age, J Pharm Health Care Sci. 2025 Mar 12;11(1):18. doi: 10.1186/s40780-025-00423-8.

Ichigo T, Suzuki A, Ibe Y, Fujii S, Fukudo M, Yoshida H, Tnaka H, Fujihara H, Yamaguchi F, Ebihara F, Maruyama T, Hamada Y, Yagi Y, Samura M, Nagumo F, Komatsu T, Tomizawa A, Takuma A, Chiba H, Nishi Y, Enoki Y, Taguchi K, Matsumoto K, Shortening the interval between the first and the second dose of vancomycin facilitates rapid achievement of the target AUC without increasing the risk of acute kidney injury, provided the AUC on the second day is appropriately controlled: a multicenter retrospective study, J Pharm Health Care Sci
. 2025 May 26;11(1):44. doi: 10.1186/s40780-025-00452-3.

Kato T, Yagi Y, Maruyama T, Hamada Y, Pharmacokinetics/Pharmacodynamics-Based Repositioning of Cefmetazole and Flomoxef in Extended-Spectrum 兝-Lactamase-Producing Enterobacterales Treatment: An Injectable Carbapenem-Sparing and Outpatient Strategy, AntibioticsOpen source preview, 2025, 14(8), 737. doi: 10.3390/antibiotics14080737

Hyodo M, Kawada K, Ishida T, Izawa-Ishizawa Y, Matoba R, Okamoto R, Jobu K, HorikawaI, Aizawa F, Yagi K, NiimuraT, Kawano Y, Abe S, Hamada Y, Goda M, Ishizawa K, Atractylodes lancea (Thunb.) DC. [Asteraceae] Rhizome-Derived Exosome-like Nanoparticles Suppress Lipopolysaccharide-Induced Inflammation by Reducing Toll-like Receptor 4 Expression in BV-2 Murine Microglial Cells, Pharmaceuticals (Basel)
. 2025 Jul 24;18(8):1099. doi: 10.3390/ph18081099

Ebihara F, Maruyama T, Kasai H, Shiokawa M, Matsunaga N, Hamada Y, Preclinical Study of Pharmacokinetic/Pharmacodynamic Analysis of Tebipenem Using Monte Carlo Simulation for Extended-Spectrum 兝-Lactamase-Producing Bacterial Urinary Tract Infections in Japanese Patients According to Renal Function, Antibiotics (Basel). 2025 Jun 26;14(7):648. doi: 10.3390/antibiotics14070648.

Morikawa S, Yagi Y, Okazaki M, Yanagisawa N, Ishida T, Jobu K, Maruyama T, Kato T, Matsushita M, ArakawaY, Yamagishi Y, Hamada Y, Rapid Therapeutic Drug Monitoring of Voriconazole Based on High-Performance Liquid Chromatography: A Single-Center Pilot Study in Outpatients, Antibiotics (Basel). 2025 May 8;14(5):474. doi: 10.3390/antibiotics14050474.

Ishigo T, Suzuki A, Ibe Y, Fujii S, Fukudo M, Yoshida H, Tanaka H, Fujihara H, Yamaguchi F, Ebihara F, Maruyama T, Yagi Y, Hamada Y, Samura M, Nagumo F, Komatsu T, Tomizawa A, Takuma A, Chiba H, Nishi Y, Igarashi Y, Enoki Y, Matsumoto K, External validation of a flowchart related to achieving the target area under the concentration-time curve for vancomycin: A retrospective multicenter study, J Infect Chemother. 2025 May;31(5):102701.

偦偺懠

戞8夞僼儗僢僔儍乕僘丒僇儞僼傽儔儞僗堦斒幮抍朄恖擔杮堛椕栻妛夛丂桪廏墘戣徿
嵅愳 嫪栫丆愇揷 抭熶丆忢晽 嫽暯丆怷戲 撜暯丆暉揷 恗丆怴栰 寬丆愳懞 婱巕丆愳揷 宧丆忋塇 揘栫丆昹揷 岾岹
擼弌寣媫惈婜偺寣埑娗棟偵偍偗傞栻嵻巘偲堛巘偺嫤摥僾儘僩僐乕儖偺桳梡惈

乹儁乕僕偺嵟弶偵栠傞乺